Biocon Expands Into Middle East With Tabuk Partnership
Tabuk Will Commercialize Select Biocon Generics In The Region
Biocon is set to bolster its planned expansion into the MENA region through a partnership with Saudi firm Tabuk Pharmaceuticals, which will commercialize select Biocon generics in the Middle East.
You may also be interested in...
Biocon Breaks Ground In Latin America Through Agreement In Brazil
Having together achieved success with biosimilar trastuzumab in Brazil, Biocon and local player Libbs Farmaceutica have reached an agreement to offer the Indian firm’s generic formulations in the market.
Biocon Takes Its Oncology Biosimilars To 30 Countries In Africa And Asia
Indian company Biocon is aiming to “deliver substantial savings to healthcare systems” by enhancing access to and availability of oncology biosimilars in 25 countries in Africa and five countries in Asia, covered under the Cancer Access Partnership, led by the Clinton Health Access Initiative.
Glucagon And Epinephrine Continue To Drive Growth At Amphastar
Amphastar has delivered another successful quarter, bolstered by sales of glucagon and epinephrine, as it prepares to roll out a number of commercially attractive products and complete a significant branded product acquisition.